Bruh, that's not how EPS and valuation of a MC is calculated....

Bruh, that's not how EPS and valuation of a MC is calculated. You think Google or Apple are generating $1T USD of revenue per year to justify their MC??? The OV market is forecast to be low because IMU hasn't entered the market, I see this as a massive positive as there are no competitors right now since BP still haven't invested in this market yet so when all of them scramble to IMU provided everything goes as expected then look out. Bile duct is very rare but also very aggressive, what does this tell us about how CF33 will respond to less aggressive cancer cell And yes, like you said we need more data for confirmation but right now they are looking very good with a CR, 2 PR and countless SD so early in Ph1 clinical trial is extremely uncommon.

IMU is expected to receive $30M from R&D rebate in total for this and last financial year so somehow you've pretty much value IMU's MC at -$30M to $30M right now. I know a few stocks who have a MC of $30-50M and are shit with a fraction potential of one of IMU's product, let alone all 5 of them (@dory and @fattchoi know about them lol).